This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sampson, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sampson, H. A.
Related Collections
Right arrow Allergy & Dermatology
PEDIATRICS Vol. 111 No. 6 June 2003, pp. 1601-1608

Anaphylaxis and Emergency Treatment

Hugh A. Sampson, MD

From the Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Mount Sinai School of Medicine, New York, New York

Food anaphylaxis is now the leading known cause of anaphylactic reactions treated in emergency departments in the United States. It is estimated that there are 30 000 anaphylactic reactions to foods treated in emergency departments and 150 to 200 deaths each year. Peanuts, tree nuts, fish, and shellfish account for most severe food anaphylactic reactions. Although clearly a form of immunoglobulin E-mediated hypersensitivity, the mechanistic details responsible for symptoms of food-induced anaphylaxis are not completely understood, and in some cases, symptoms are not seen unless the patient exercises within a few hours of the ingestion. At the present time, the mainstays of therapy include educating patients and their caregivers to strictly avoid food allergens, to recognize early symptoms of anaphylaxis, and to self-administer injectable epinephrine. However, clinical trials are now under way for the treatment of patients with peanut anaphylaxis using recombinant humanized anti-immunoglobulin E antibody therapy, and novel immunomodulatory therapies are being tested in animal models of peanut-induced anaphylaxis.

Key Words: anaphylaxis • immunoglobulin E • anti-IgE antibodies • food hypersensitivity • elimination diet • EpiPen

Abbreviations: IgE, immunoglobulin E

Received for publication Sep 11, 2002; Accepted Oct 30, 2002.




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
M. Erlewyn-Lajeunesse, J. Bonhoeffer, J. U Ruggeberg, and P. T Heath
Anaphylaxis as an adverse event following immunisation
J. Clin. Pathol., July 1, 2007; 60(7): 737 - 739.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. H. Sicherer, F. E. R. Simons, and the Section on Allergy and Immunology
Self-injectable Epinephrine for First-Aid Management of Anaphylaxis
Pediatrics, March 1, 2007; 119(3): 638 - 646.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. L. McIntyre, A. H. Sheetz, C. R. Carroll, and M. C. Young
Administration of Epinephrine for Life-Threatening Allergic Reactions in School Settings
Pediatrics, November 1, 2005; 116(5): 1134 - 1140.
[Abstract] [Full Text] [PDF]